FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0283								
Estimated average burden								
hours per response:	0.5							

					OI 3	Sectio)II 30(II) C	טו ונופ	investment C	ompany Act	01 1940						
1. Name and Address of Reporting Person* Fanucci Marsha				2. Issuer Name and Ticker or Trading Symbol Cyclerion Therapeutics, Inc. [CYCN]						(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
ranucc	<u>1 Iviai Siia</u>										-		X Directo	or		10% Ov	vner
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/14/2022							Officer below)	(give title		Other (s below)	specify	
C/O CYCLERION THERAPEUTICS, INC.				00/	14/2(<i>J</i> 22											
245 FIRST STREET, 18TH FLOOR				If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable							
(Street)												Line	,	iled by One	D	utina Danas	
CAMBR	IDGE M	ÍΑ	02142											iled by More		Ü	I
(City)	(S	tate)	(Zip)										1 61501	•			
		Tab	le I - Non-I	Deriva	tive	Sec	curities	s Ac	quired, Di	sposed c	of, or Be	neficiall	y Owned	l			
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date)			ate	Execution Date,		Code (Instr. 5)				Benefici	es Formially (D) (Following (I) (II)		m: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code V	Amount	(A) or (D)	Price	Transact (Instr. 3	tion(s)			(instr. 4)		
		-	Table II - De						uired, Dis s, options,				Owned				
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction 3A. Deemed Execution Date, curity or Exercise (Month/Day/Year) if any		te, Tra	5. Number of Ocide (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Co	ode '	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$0.53	06/14/2022		I	A		20,000		(1)	06/14/2032	Common Stock	20,000	\$0	20,000)	D	

Explanation of Responses:

1. The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

/s/ Gary J. Simon, Attorney-in-

Fact

06/16/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.